Klara Klein
Klara Klein is a researcher at the University of North Carolina's School of Medicine. She has been involved in groundbreaking studies exploring the effects of semaglutide, a medication originally developed for type 2 diabetes, on alcohol consumption and cravings. Her recent work suggests that semaglutide may have the potential to aid in treating alcohol use disorders, highlighting the need for further research to understand its efficacy and safety in this context.
Not in the pool (under ¢1).
Recent news mentions
Klara Klein is a co-author of the study discussing the effects of the medication on alcohol consumption.
Популярні препарати для схуднення потенційно змушують потяг до вживання алкоголю — дослідження
Ukraine· 2025-02-13
Klara Klein is the study leader who reported on the potential of semaglutide for treating alcohol use disorder.
Ozempic shows some promise for alcohol use disorder
Canada· 2025-02-12Klara Klein is the senior author of the study suggesting the potential of semaglutide for treating alcohol use disorder.
Weight-loss jabs may help reduce alcohol intake, study finds | Alcohol
United Kingdom· 2025-02-12
Klara Klein from the University of North Carolina stated that the data shows the potential of semaglutide and similar drugs to fill the treatment gap for alcohol use disorders.
Zdravila za hujšanje uspešno gasijo tudi željo po alkoholu
Slovenia· 2025-02-12